Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
13 févr. 2023 07h00 HE
|
Clene Inc.
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effectMRI results...
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
08 févr. 2023 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the...
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
07 févr. 2023 07h00 HE
|
AC Immune SA
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer...
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
31 janv. 2023 07h05 HE
|
uniQure Inc.
~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS...
Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS
17 janv. 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company...
FDA’s Peter Marks, M.D., Ph.D. to deliver Keynote Address at 2023 Muscular Dystrophy Association Clinical & Scientific Conference
10 janv. 2023 06h00 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific...
Muscular Dystrophy Association Elects Governor Brad Henry as Chairman and Christopher Rosa, Ph.D. as Vice Chairman of the Board of Directors
09 janv. 2023 09h20 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the election of new Board of Directors leadership. Governor Brad Henry will now serve as...
Eledon Pharmaceuticals Provides Business and Pipeline Updates
09 janv. 2023 08h31 HE
|
Eledon Pharmaceuticals, Inc.
Company plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Continued enrollment in open-label Phase 1b kidney transplant trial with initial data...
Athira Pharma Provides 2023 Pipeline Outlook
05 janv. 2023 07h00 HE
|
Athira Pharma, Inc.
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase...
Le masitinib reçoit la désignation de médicament orphelin pour le traitement de la sclérose latérale amyotrophique en Suisse
27 déc. 2022 13h04 HE
|
AB Science
COMMUNIQUE DE PRESSE LE MASITINIB REÇOIT LA DÉSIGNATION DE MÉDICAMENT ORPHELIN POUR LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) EN SUISSE Paris, 26 décembre 2022, 19h AB Science SA...